journal article·2026-04-20Open access

In vitro tolerability of soluble silicic acid and tetraethyl orthosilicate in ocular epithelial cells

Aleksandra Poluianova, Alexandra Robciuc, Ville Pollari, Jukka A. O. Moilanen, Kai Kaarniranta, Lasse Leino

Abstract

Biodegradable silica microparticles (SiMPs) are a promising carrier matrix for controlled ocular drug delivery. In tissues, SiMPs degrade into silicic acid (SiA), a soluble inorganic weak acid. This study evaluated the in vitro toxicity and tolerability of SiA and SiMPs' precursor, tetraethyl orthosilicate (TEOS), in human corneal epithelial cells (HCE-2) and retinal pigment epithelial cells (ARPE-19). Cells were exposed to serial dilutions of SiA and TEOS. Cell viability was assessed after 24, 48, and 72 h using the alamarBlue assay, while membrane integrity was analyzed through LDH release. To evaluate cellular stress from SiA and TEOS, levels of pro-inflammatory, apoptosis, and heat shock stress response markers were measured. Neither viability assay revealed significant differences in survival rates between the control group and 30 µg/mL SiA in ARPE-19 and HCE-2 cells at all time points. ARPE-19 viability decreased with low SiA concentrations, but this was not supported by LDH release or caspase-3 activation. Inflammatory markers IL-6, IL-8, and MCP-1 secretion or heat shock protein 70 expression levels were not changed in either cell line in response to SiA. Conversely, TEOS reduced cell viability at high concentrations (0.6-2.4 mg/mL) and affected the cytokine response in both cell lines. Our results indicate that both cell lines can tolerate SiA concentrations up to 30 µg/mL. In contrast, TEOS showed toxicity at concentrations above 0.6 mg/mL, which greatly exceeds expected levels in the SiMP formulation. These findings support the use of SiMPs as drug delivery vehicles in ophthalmic formulations.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Silicon Effects in Agriculture · Aluminum toxicity and tolerance in plants and animals · Silicone and Siloxane Chemistry

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (32)

Show source-provided references
1. Gote V, Sikder S, Sicotte J, Pal D. Ocular Drug Delivery: Present Innovations and Future Challenges. J Pharmacol Exp Ther. 2019;370:602–24. https://doi.org/10.1124/jpet.119.256933.10.1124/jpet.119.256933 ↗
2. Hedges TR. Treatment of optic neuropathy, has its time come?. Semin Ophthalmol. 2002;17:1–3. https://doi.org/10.1076/soph.17.1.1.10291.10.1076/soph.17.1.1.10291 ↗
3. Kaarniranta K, Xu H, Kauppinen A. Mechanistical retinal drug targets and challenges. Adv Drug Deliv Rev. 2018;126:177–84. https://doi.org/10.1016/j.addr.2018.04.016.10.1016/j.addr.2018.04.016 ↗
4. Avetisov SE, Erichev VP, Antonov AA, Poleva RP, Kozlova IV, Makarova AS. Modern achievements in the diagnosis and treatment of glaucoma. Vestn Oftalmol. 2023;139:96–106. https://doi.org/10.17116/oftalma202313903296.10.17116/oftalma202313903296 ↗
5. Leong Y-Y, Tong L. Barrier function in the ocular surface: from conventional paradigms to new opportunities. Ocul Surf. 2015;13:103–9. https://doi.org/10.1016/j.jtos.2014.10.003.10.1016/j.jtos.2014.10.003 ↗
6. Fagan XJ, Al-Qureshi S. Intravitreal injections: a review of the evidence for best practice. Clin Exp Ophthalmol. 2013;41:500–7. https://doi.org/10.1111/ceo.12026.10.1111/ceo.12026 ↗
7. Pagels RF, Prud’homme RK. Polymeric nanoparticles and microparticles for the delivery of peptides, biologics, and soluble therapeutics. J Controlled Release. 2015;219:519–35. https://doi.org/10.1016/j.jconrel.2015.09.001.10.1016/j.jconrel.2015.09.001 ↗
8. Zuppolini S, Maya IC, Diodato L, Guarino V, Borriello A, Ambrosio L. Self-associating cellulose-graft-poly(ε-caprolactone) to design nanoparticles for drug release. Mater Sci Eng C. 2020;108:110385 https://doi.org/10.1016/j.msec.2019.110385.10.1016/j.msec.2019.110385 ↗
9. Noppari P, Forsback AP, Terjung C, Marttila A, Leino L, Unger F, et al. Development of injectable long-acting controlled release intravitreal depot of BAY224 using biodegradable silica microparticle-silica hydrogel composite. Invest Ophthalmol Vis Sci. 2020;61:1357.
10. Awwad S, Mohamed Ahmed AHA, Sharma G, Heng JS, Khaw PT, Brocchini S, et al. Principles of pharmacology in the eye. Br J Pharm. 2017;174:4205–23. https://doi.org/10.1111/bph.14024.10.1111/bph.14024 ↗
11. Kaarniranta K, Reay M, Leino L, Kievari S, Hartikainen A, Martikainen O, et al. (2024) Clinical phase 1 safety and tolerability evaluation of sustained release silica composite eye drops in human subjects. Acta Ophthalmol 102:. https://doi.org/10.1111/aos.1606010.1111/aos.16060 ↗
12. Akieh-Pirkanniemi MN, Poluianova A, Su P, Vaahtio M, Arstila H, Leino L. Development and preclinical safety testing of biodegradable Silica Eye Drop as an ophthalmic carrier matrix. 2025.10.21203/rs.3.rs-7880491/v1 ↗
13. Sun Y, Huffman K, Freeman WR, Sailor MJ, Cheng L. Intravitreal safety profiles of sol-gel mesoporous silica microparticles and the degradation product (Si(OH)4). Drug Deliv. 2020;27:703–11. https://doi.org/10.1080/10717544.2020.1760401.10.1080/10717544.2020.1760401 ↗
14. Winter S, Dargelas F, Leino L, Pollari V, Reay M, Assmuth T, et al. (2025) Assessment of silica as an intravitreal drug delivery vehicle in a preclinical in vivo tolerability study. Acta Ophthalmol. 103: https://doi.org/10.1111/aos.1738110.1111/aos.17381 ↗
15. Jurkić LM, Cepanec I, Pavelić SK, Pavelić K. Biological and therapeutic effects of ortho-silicic acid and some ortho-silicic acid-releasing compounds: New perspectives for therapy. Nutr Metab. 2013;10:2 https://doi.org/10.1186/1743-7075-10-2.10.1186/1743-7075-10-2 ↗
16. Nieto A, Hou H, Sailor MJ, Freeman WR, Cheng L. Ocular silicon distribution and clearance following intravitreal injection of porous silicon microparticles. Exp Eye Res. 2013;116:161–8. https://doi.org/10.1016/j.exer.2013.09.001.10.1016/j.exer.2013.09.001 ↗
17. Low SP, Voelcker NH, Canham LT, Williams KA. The biocompatibility of porous silicon in tissues of the eye. Biomaterials. 2009;30:2873–80. https://doi.org/10.1016/j.biomaterials.2009.02.008.10.1016/j.biomaterials.2009.02.008 ↗
18. Ju M, Li Y, Yu L, Wang C, Zhang L. Two-Phase Diffusion Technique for the Preparation of Ultramacroporous/Mesoporous Silica Microspheres via Interface Hydrolysis, Diffusion, and Gelation of TEOS. Langmuir. 2018;34:2046–56. https://doi.org/10.1021/acs.langmuir.7b03764.10.1021/acs.langmuir.7b03764 ↗
19. Smedowski A, Paterno JJ, Toropainen E, Sinha D, Wylegala E, Kaarniranta K. Excipients of preservative-free latanoprost induced inflammatory response and cytotoxicity in immortalized human HCE-2 corneal epithelial cells. J Biochem Pharm Res. 2014;2:175–84.
20. Kinnunen K, Kauppinen A, Piippo N, Koistinen A, Toropainen E, Kaarniranta K. Cationorm shows good tolerability on human HCE-2 corneal epithelial cell cultures. Exp Eye Res. 2014;120:82–9. https://doi.org/10.1016/j.exer.2014.01.006.10.1016/j.exer.2014.01.006 ↗
21. Toppila M, Ranta-aho S, Kaarniranta K, Hytti M, Kauppinen A. Metformin Alleviates Inflammation and Induces Mitophagy in Human Retinal Pigment Epithelium Cells Suffering from Mitochondrial Damage. Cells. 2024;13:1433 https://doi.org/10.3390/cells13171433.10.3390/cells13171433 ↗
22. Duivenvoorden WCM, Middleton A, Kinrade SD. Divergent effects of orthosilicic acid and dimethylsilanediol on cell survival and adhesion in human osteoblast-like cells. J Trace Elem Med Biol. 2008;22:215–23. https://doi.org/10.1016/j.jtemb.2008.02.001.10.1016/j.jtemb.2008.02.001 ↗
23. Mayne AH, Bayliss SC, Barr P, Tobin M, Buckberry LD. Biologically interfaced porous silicon devices. Phys Status Solidi. 2000;182:505–13.10.1002/1521-396X(200011)182:1<505::AID-PSSA505>3.0.CO;2-# ↗
24. Tanaka T, Tanigawa T, Nose T, Imai S, Hayashi Y. In vitro cytotoxicity of silicic acid in comparison with that of selenious acid. J Trace Elem Exp Med. 1994;7:101–11.
25. American Chemical Society. Tetraethyl orthosilicate. Molecule of the Week Archive. ACS Molecule of the Week Archive. 2025.
26. Nakashima H. Time course of effects of tetraethoxysilane (TEOS) on the kidney and blood silicon concentration in mice. Arch Toxicol. 1994;69:59–64. https://doi.org/10.1007/s002040050138.10.1007/s002040050138 ↗
27. Nakashima H, Omae K, Sakai T, Yamazaki K, Sakurai H. Acute and subchronic inhalation toxicity of tetraethoxysilane (TEOS) in mice. Arch Toxicol. 1994;68:277–83. https://doi.org/10.1007/s002040050069.10.1007/s002040050069 ↗
28. Sigma-Aldrich (2024) Tetraethyl Orthosilicate Safety Data Sheet (Product No. 86578).
29. Korhonen E, Rönkkö S, Hillebrand S, Riikonen J, Xu W, Järvinen K, et al. Cytotoxicity assessment of porous silicon microparticles for ocular drug delivery. Eur J Pharmaceut Biopharmaceut. 2016;100:1–8. https://doi.org/10.1016/j.ejpb.2015.11.020.10.1016/j.ejpb.2015.11.020 ↗
30. Park J-H, Jeong H, Hong J, Chang M, Kim M, Chuck RS, et al. The Effect of Silica Nanoparticles on Human Corneal Epithelial Cells. Sci Rep. 2016;6:37762. https://doi.org/10.1038/srep37762.10.1038/srep37762 ↗
31. Beamer GL, Seaver BP, Jessop F, Shepherd DM, Beamer CA. Acute Exposure to Crystalline Silica Reduces Macrophage Activation in Response to Bacterial Lipoproteins. Front Immunol. 2016;7:49 https://doi.org/10.3389/fimmu.2016.00049.10.3389/fimmu.2016.00049 ↗
32. Kusaka T, Nakayama M, Nakamura K, Ishimiya M, Furusawa E, Ogasawara K. Effect of Silica Particle Size on Macrophage Inflammatory Responses. PLoS One. 2014;9:e92634 https://doi.org/10.1371/journal.pone.0092634.10.1371/journal.pone.0092634 ↗